美国难治性和非难治性慢性特发性荨麻疹真实世界临床负担与医疗资源使用研究数据

数据集获取（Figshare）

• 源站标题：Exploring the real-world profile of refractory and non-refractory chronic idiopathic urticaria in the USA: clinical burden and healthcare resource use
• DOI：10.6084/m9.figshare.7756793.v2
• 发布日期：2019-03-28
• 文件数：3 个
• 文件总体积：272.54 KB
• 源站页面：https://tandf.figshare.com/articles/dataset/Exploring_the_real-world_profile_of_refractory_and_non-refractory_chronic_idiopathic_urticaria_in_the_USA_clinical_burden_and_healthcare_resource_use/7756793

命令行下载

curl -L -o "icmo_a_1586222_sm3981.tif" "https://ndownloader.figshare.com/files/14730233"
curl -L -o "icmo_a_1586222_sm8395.tif" "https://ndownloader.figshare.com/files/14442041"
curl -L -o "icmo_a_1586222_sm8393.docx" "https://ndownloader.figshare.com/files/14442047"

文件清单

• icmo_a_1586222_sm3981.tif（143.99 KB）
• icmo_a_1586222_sm8395.tif（94.66 KB）
• icmo_a_1586222_sm8393.docx（33.88 KB）

文件总体积 272.54 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Introduction: Chronic idiopathic/spontaneous urticaria (CIU/CSU) is a debilitating skin condition that is burdensome for patients and healthcare providers. We aimed to describe clinical characteristics, consultation patterns and healthcare resource utilization in real-world US patients with refractory and non-refractory CIU/CSU.
Methods: Data was collected from the Adelphi Real World 2015 Urticaria Disease Specific Programme. Physicians completed patient record forms (PRFs) for the next four patients consulting with non-refractory CIU/CSU and the next six with refractory CIU/CSU; patients were considered refractory if symptomatic and on treatment step ≥2. The same patients were asked to complete patient self-completion (PSC) forms describing how CIU/CSU affected them.
Results: Seventeen physicians (15 allergists; 2 dermatologists) completed 184 PRFs (108 refractory CIU/CSU; 76 non-refractory CIU/CSU); 140 patients completed PSC forms (93 refractory CIU/CSU; 47 non-refractory CIU/CSU). Mean time from first consultation to diagnosis was 13.5 (SD 28.3) weeks; mean time from diagnosis to first treatment was 16.0 (SD 37.9) weeks. Patients with refractory CIU/CSU were more likely to initially consult primary care physicians than those with non-refractory CIU/CSU (51% and 28%, respectively). The most common symptoms were itching, sleep problems and anxiety/distress, affecting 75%, 23% and 18%, respectively. Patient-perceived disease severity was greater than physician-perceived severity (refractory CIU/CSU kappa 0.1512; non-refractory CIU/CSU 0.1590).
Conclusions: Patients with CIU/CSU in this real-world study – particularly those with refractory CIU/CSU – were slow to receive specialist care and had substantial symptom burdens; patient–physician perception of disease severity was discordant. Earlier diagnosis of CIU/CSU may lead to timely use of CIU/CSU therapies.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.7756793.v2（source: https://tandf.figshare.com/articles/dataset/Exploring_the_real-world_profile_of_refractory_and_non-refractory_chronic_idiopathic_urticaria_in_the_USA_clinical_burden_and_healthcare_resource_use/7756793）。